Previous 10 | Next 10 |
LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1) There are currently no approved treatments for STGD1 Approximately 30,000 patients in the U.S. suffer from STGD1 A 2-year Phase 2 trial in adolescent...
Meta ( NASDAQ: META ) represented one of the biggest name stocks seeing a midday move on Friday. Shares of the Facebook parent edged lower as it cut back on its hiring plans in the face of a cautious economic forecast. Meanwhile, PureCycle ( PCT ) also made the list of midda...
Benchmark analyst Bruce Jackson initiated coverage of Belite Bio ( BLTE ) with a Buy rating and $57 price target. The clinical-stage biopharmaceutical company's lead asset is LBS-008, which is designed to slow retinal degeneration in dry Age-Related Macular Degeneration, or d...
Belite Bio Inc (NSC:BLTE) is a company whose shares are active, trading 100.7% higher to $30.10. Belite Bio Inc share prices have moved between a 52-week high of $31.27 and a 52-week low of $8.80 and are now trading 242% above that low price at $30.10 per share. Receive IBN Spotlights ...
Belite Bio Inc (NSC:BLTE) is one of today's biggest movers, up 97.0% to $29.55. In the past 52 weeks, shares of Belite Bio Inc have traded between a low of $8.80 and a high of $30.99 and is now at $29.55, which is 236% above that low price. Receive IBN Spotlights - "Bite Size" Small, M...
Gainers: Evoke Pharma EVOK +52%. Zynerba Pharmaceuticals (ZYNE) +18%. LifeMD (LFMD) +13%. Vivos Therapeutics (VVOS) +12%. ACADIA Pharmaceuticals ACAD +11%. Losers: 180 Life Sciences (ATNF) -31%. Belite Bio (BLTE) -19%. VectivBio VECT -14%...
Gainers: Revlon (REV) +98%. biote (BTMD) +61%. Cepton (CPTN) +40%. Alpha Teknova (TKNO) +23%. New Oriental Education & Technology (EDU) +23%. Owlet (OWLT) +21%. Belite Bio (BLTE) +21%. Kaival Brands Innovations Group (KAVL) +20%. iQIYI (IQ) +17%. NIO (NIO) +16%. Redbox Entertainment (RDBX...
Drug developer Belite Bio (BLTE) shares jumped 13% Monday amid a significant sell-off in the broader market, trading 247% above its initial public offering price. Belite (BLTE) shares opened at $18.80, climbing to a high of $24.75 in early afternoon trading. The stock recently changed hands a...
Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%. Neptune Wellness Solutions (NEPT) -19%. Sc...
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabol...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...